North America Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

August 2020 | 121 pages | ID: NA5C9CB0F8C6EN
GMD Research

Abstracts

North America oral antibiotics market is expected to grow by 2.8% annually in the forecast period and reach $6,122.9 million by 2030 driven by rising complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure.

Highlighted with 28 tables and 60 figures, this 121-page report “North America Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America oral antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country.

Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cephalosporin

• Cefuroxime Axetil
• Cephalexin
• Cefixime
• Cefpodoxime
• Other Cephalosporin

Penicillin
Macrolides
Tetracycline
Quinolones
Sulfonamides
Aminoglycosides
Other Drug Classes

Based on Action Mechanism, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Cell Wall Synthesis Inhibitors
• Mycolic Acid Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Protein Synthesis Inhibitors
• Other Mechanisms

Based on Drug Origin, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Natural Antibiotics
• Semi-synthetic Antibiotics
• Synthetic Antibiotics

Based on Activity Spectrum, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Broad-spectrum Antibiotics
• Narrow-spectrum Antibiotics

Based on Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Urinary Tract Infections (UTIS)

• Upper Respiratory Tract Infections (URTI)
• Lower Respiratory Tract Infections (LRTIs)

Dental Infections

• Monotherapies
• Combined Therapies

Respiratory Tract Infections (RTIS)
Other Applications

Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

• Brand Antibiotics
• Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

• U.S.
• Canada
• Mexico

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America oral antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF NORTH AMERICA MARKET BY DRUG CLASS

3.1 Market Overview by Drug Class
3.2 Cephalosporin
3.3 Penicillin
3.4 Macrolides
3.5 Tetracycline
3.6 Quinolones
3.7 Sulfonamides
3.8 Aminoglycosides
3.9 Other Drug Classes

4 SEGMENTATION OF NORTH AMERICA MARKET BY ACTION MECHANISM

4.1 Market Overview by Action Mechanism
4.2 Cell Wall Synthesis Inhibitors
4.3 Mycolic Acid Inhibitors
4.4 RNA Synthesis Inhibitors
4.5 DNA Synthesis Inhibitors
4.6 Protein Synthesis Inhibitors
4.7 Other Mechanisms

5 SEGMENTATION OF NORTH AMERICA MARKET BY DRUG ORIGIN

5.1 Market Overview by Drug Origin
5.2 Natural Antibiotics
5.3 Semi-synthetic Antibiotics
5.4 Synthetic Antibiotics

6 SEGMENTATION OF NORTH AMERICA MARKET BY ACTIVITY SPECTRUM

6.1 Market Overview by Activity Spectrum
6.2 Broad-spectrum Antibiotics
6.3 Narrow-spectrum Antibiotics

7 SEGMENTATION OF NORTH AMERICA MARKET BY APPLICATION

7.1 Market Overview by Application
7.2 Urinary Tract Infections (UTIS)
7.3 Dental Infections
  7.3.1 Monotherapies for Dental Infections
  7.3.2 Combined Therapies for Dental Infections
7.4 Respiratory Tract Infections (RTIS)
  7.4.1 Upper Respiratory Tract Infections (URTI)
  7.4.2 Lower Respiratory Tract Infections (LRTIs)
7.5 Other Applications

8 SEGMENTATION OF NORTH AMERICA MARKET BY DRUG TYPE

8.1 Market Overview by Drug Type
8.2 Brand Antibiotics
8.3 Generic Antibiotics

9 NORTH AMERICA MARKET 2019-2030 BY COUNTRY

9.1 Overview of North America Market
9.2 U.S.
9.3 Canada
9.4 Mexico

10 COMPETITIVE LANDSCAPE

10.1 Overview of Key Vendors
10.2 New Product Launch, Partnership, Investment, and M&A
10.3 Company Profiles
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

11 INVESTING IN NORTH AMERICA MARKET: RISK ASSESSMENT AND MANAGEMENT

11.1 Risk Evaluation of North America Market
11.2 Critical Success Factors (CSFs)
Related Reports and Products

List Of Tables

LIST OF TABLES

Table 1. Snapshot of North America Oral Antibiotics Market, 2019-2030
Table 2. Main Product Trends and Market Opportunities in North America Oral Antibiotics Market
Table 3. North America Oral Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 4. North America Oral Antibiotics Market: Cephalosporin by Molecule, 2019-2030, $ mn
Table 5. North America Oral Antibiotics Market by Action Mechanism, 2019-2030, $ mn
Table 6. North America Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 7. North America Oral Antibiotics Market by Activity Spectrum, 2019-2030, $ mn
Table 8. North America Oral Antibiotics Market by Application, 2019-2030, $ mn
Table 9. North America Oral Antibiotics Market: Dental Infections by Type, 2019-2030, $ mn
Table 10. North America Oral Antibiotics Market: Respiratory Tract Infections (RTIS) by Type, 2019-2030, $ mn
Table 11. North America Oral Antibiotics Market by Drug Type, 2019-2030, $ bn
Table 12. North America Oral Antibiotics Market by Country, 2019-2030, $ bn
Table 13. U.S. Oral Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 14. U.S. Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 15. U.S. Oral Antibiotics Market by Application, 2019-2030, $ mn
Table 16. Canada Oral Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 17. Canada Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 18. Canada Oral Antibiotics Market by Application, 2019-2030, $ mn
Table 19. Mexico Oral Antibiotics Market by Drug Class, 2019-2030, $ mn
Table 20. Mexico Oral Antibiotics Market by Drug Origin, 2019-2030, $ mn
Table 21. Mexico Oral Antibiotics Market by Application, 2019-2030, $ mn
Table 22. Abbott Laboratories: Company Snapshot
Table 23. Abbott Laboratories: Business Segmentation
Table 24. Abbott Laboratories: Product Portfolio
Table 25. Abbott Laboratories: Revenue, 2016-2018, $ mn
Table 26. Abbott Laboratories: Recent Developments
Table 27. Risk Evaluation for Investing in North America Market, 2019-2030
Table 28. Critical Success Factors and Key Takeaways

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. North America Oral Antibiotics Market, 2019-2030, $ mn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of North America Oral Antibiotics Market
Figure 8. GDP per capita in the World, 1960-2018, $ thousand
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million
Figure 10. Primary Restraints and Impact Factors of North America Oral Antibiotics Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of North America Oral Antibiotics Market
Figure 13. Breakdown of North America Oral Antibiotics Market by Drug Class, 2019-2030, % of Revenue
Figure 14. North America Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%)
Figure 15. North America Oral Antibiotics Market: Cephalosporin, 2019-2030, $ mn
Figure 16. North America Oral Antibiotics Market: Penicillin, 2019-2030, $ mn
Figure 17. North America Oral Antibiotics Market: Macrolides, 2019-2030, $ mn
Figure 18. North America Oral Antibiotics Market: Tetracycline, 2019-2030, $ mn
Figure 19. North America Oral Antibiotics Market: Quinolones, 2019-2030, $ mn
Figure 20. North America Oral Antibiotics Market: Sulfonamides, 2019-2030, $ mn
Figure 21. North America Oral Antibiotics Market: Aminoglycosides, 2019-2030, $ mn
Figure 22. North America Oral Antibiotics Market: Other Drug Classes, 2019-2030, $ mn
Figure 23. Breakdown of North America Oral Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue
Figure 24. North America Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%)
Figure 25. North America Oral Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn
Figure 26. North America Oral Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn
Figure 27. North America Oral Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn
Figure 28. North America Oral Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn
Figure 29. North America Oral Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn
Figure 30. North America Oral Antibiotics Market: Other Mechanisms, 2019-2030, $ mn
Figure 31. Breakdown of North America Oral Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue
Figure 32. North America Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%)
Figure 33. North America Oral Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn
Figure 34. North America Oral Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn
Figure 35. North America Oral Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn
Figure 36. Breakdown of North America Oral Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue
Figure 37. North America Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%)
Figure 38. North America Oral Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn
Figure 39. North America Oral Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn
Figure 40. Breakdown of North America Oral Antibiotics Market by Application, 2019-2030, % of Revenue
Figure 41. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 42. North America Oral Antibiotics Market: Urinary Tract Infections (UTIS), 2019-2030, $ mn
Figure 43. North America Oral Antibiotics Market: Dental Infections, 2019-2030, $ mn
Figure 44. North America Oral Antibiotics Market: Monotherapies for Dental Infections, 2019-2030, $ mn
Figure 45. North America Oral Antibiotics Market: Combined Therapies for Dental Infections, 2019-2030, $ mn
Figure 46. North America Oral Antibiotics Market: Respiratory Tract Infections (RTIS), 2019-2030, $ mn
Figure 47. North America Oral Antibiotics Market: Upper Respiratory Tract Infections (URTI), 2019-2030, $ mn
Figure 48. North America Oral Antibiotics Market: Lower Respiratory Tract Infections (LRTIs), 2019-2030, $ mn
Figure 49. North America Oral Antibiotics Market: Other Applications, 2019-2030, $ mn
Figure 50. Breakdown of North America Oral Antibiotics Market by Drug Type, 2019-2030, % of Revenue
Figure 51. North America Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%)
Figure 52. North America Oral Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn
Figure 53. North America Oral Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn
Figure 54. Breakdown of North America Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue
Figure 55. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 56. U.S. Oral Antibiotics Market, 2019-2030, $ bn
Figure 57. Rising Incidence of Infectious Disease in U.S.
Figure 58. Canada Oral Antibiotics Market, 2019-2030, $ bn
Figure 59. Oral Antibiotics Market in Mexico, 2015-2030, $ bn
Figure 60. Growth Stage of North America Oral Antibiotics Industry over the Forecast Period


COMPANIES MENTIONED

Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.